Impact of Food Supplementation on Quality of Life in Patients With Endometriosis and Pelvic Pain.
NCT07393958
· ctgov
recruiting
- Enrollment
- 60
- Start
- 2026-02-26
- Completion
- 2027-09-15
- Last updated
- 2026-10-30
- Has results
- False
- Countries
- Spain
Conditions
Tagged with
Interventions
-
Food supplement (T1675)
DIETARY_SUPPLEMENT
Doliral is the food supplement, which is the investigational product at this study.
-
Placebo
OTHER
Placebo is the control treatment.
Eligibility criteria
Inclusion Criteria:
* Women of reproductive age with diagnosed endometriosis stage I, II, or III, according to the American Society for Reproductive Medicine (ASRM) classification.
* Women with a diagnosis of endometriosis confirmed by laparoscopy or, in the absence of laparoscopy, by magnetic resonance imaging (MRI) and/or ultrasound.
* Presence of pelvic pain (VAS \> 4) during the last three months.
* No indication for surgical intervention at the time of inclusion in the study.
* Patients who are able to provide informed consent.
Exclusion Criteria:
* Patients under 18 years of age.
* Use of analgesic or anti-inflammatory pharmacological treatment, except for ibuprofen at doses up to 600 mg/day or naproxen at doses up to 500 mg/day.
* Surgery within the year prior to inclusion, performed for therapeutic purposes related to the pathology under study.
* Initiation or discontinuation of hormone therapy within the three months prior to inclusion in the study.
* Patients with known allergy or hypersensitivity to Doliral®.
* Pregnant or breastfeeding patients.
* Patients on sick leave: \> 1 year, or With no intention of returning to work, or Undergoing a disability or permanent incapacity assessment process.
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of ClinicalTrials.gov / U.S. National Library of Medicine
Courtesy of ClinicalTrials.gov / U.S. National Library of Medicine